Who Owns Tandem Diabetes Care Company?

Tandem Diabetes Care Bundle

Get Full Bundle:

	PESTLE	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns Tandem Diabetes Care?

Understanding a company's ownership is key to grasping its strategic direction. For Tandem Diabetes Care, a leader in diabetes management devices, this insight is vital.

Tandem Diabetes Care, Inc., established in 2006 and incorporated in 2008, has become a prominent name in diabetes technology. Its journey from a startup to a publicly traded entity on the Nasdaq under TNDM reflects significant growth and evolving stakeholder interests.

As of July 18, 2025, Tandem Diabetes Care had a market capitalization of approximately $984 million. The company's financial performance, with trailing twelve-month revenue of $983 million as of March 31, 2025, underscores its market position. With 2,650 employees as of 2024, Tandem Diabetes Care is a substantial operation. Its product innovations, such as those detailed in the Tandem Diabetes Care PESTEL Analysis, are central to its value proposition.

The ownership of Tandem Diabetes Care is primarily distributed among institutional investors, with Vanguard Group, Inc. holding the largest stake. Other significant institutional holders include BlackRock, Inc., and The Vanguard Group. Retail investors also form a notable portion of the shareholder base. The company's Board of Directors, comprising experienced professionals, oversees its strategic decisions, influencing its direction and commitment to innovation in diabetes care.

Tandem Diabetes Care's journey began in 2006 under the name Phluid, Inc., founded by engineers aiming to enhance insulin delivery systems. Paul Diperna is recognized as a founder, with Kim Blickenstaff joining in 2007 as President and CEO, driving product development with a focus on market research and user experience inspired by consumer electronics.

Founding Vision

The company's inception as Phluid, Inc. in 2006 was driven by a group of engineers identifying a need for improved insulin pumping technology.

Leadership Evolution

Kim Blickenstaff's arrival in 2007 as President and CEO was crucial in shaping the company's product strategy and market approach.

Brand Transition

In 2008, Phluid, Inc. officially became Tandem Diabetes Care, Inc., signaling a commitment to a user-centric diabetes management approach.

Early Funding Rounds

The company secured approximately $101 million across six funding rounds before its public offering.

Key Early Investors

Prominent institutional investors like CRG, TPG, and Domain Associates were instrumental in early funding.

Product Milestones

These early investments supported the development of products like the t:slim Insulin Pump, which received FDA approval in 2012.

The company's early focus was on developing user-friendly and aesthetically pleasing insulin pumps, drawing inspiration from consumer electronics design principles. This approach was central to their Growth Strategy of Tandem Diabetes Care, aiming to make diabetes management more accessible and integrated into daily life.

Founding and Early Development

Tandem Diabetes Care, initially Phluid, Inc., was established in 2006 by engineers focused on improving insulin delivery. Kim Blickenstaff joined in 2007, guiding the company's product vision.

• Founded as Phluid, Inc. in 2006.
• Paul Diperna is listed as a founder.
• Kim Blickenstaff joined as President and CEO in 2007.
• Company rebranded to Tandem Diabetes Care, Inc. in 2008.
• Early funding totaled approximately $101 million.
• Key early investors included CRG, TPG, and Domain Associates.
• The t:slim Insulin Pump received FDA approval in 2012.

Tandem Diabetes Care SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Tandem Diabetes Care, Inc. transitioned to a publicly traded entity on November 14, 2013, commencing trading on the NASDAQ Global Market under the ticker TNDM. This initial public offering involved 8,000,000 shares at $15.00 per share, successfully raising approximately $100 million and marking a significant shift in its ownership landscape.

The current ownership structure of Tandem Diabetes Care is heavily weighted towards institutional investors, who collectively hold a substantial portion of the company's stock. As of March 31, 2025, these entities owned approximately 55.88% of the outstanding shares, indicating their significant influence on the company's direction and governance. This widespread institutional backing suggests a strong belief in the company's long-term prospects, as detailed in its Revenue Streams & Business Model of Tandem Diabetes Care.

Tandem Diabetes Care Major Shareholders

Institutional investors are the primary owners of Tandem Diabetes Care, holding over half of the company's shares. This concentration of ownership means that major investment firms play a crucial role in the company's strategic decisions.

• BlackRock, Inc. is a leading institutional investor, holding 16.56% of the shares.
• The Vanguard Group, Inc. follows with 10.95% ownership.
• Sessa Capital (Master) L.P. / Sessa Capital IM, L.P. holds 6.71% of the company's stock.
• Other significant institutional investors include GW&K Investment Management, LLC (4.30%), ArrowMark Colorado Holdings, LLC (4.08%), and State Street Global Advisors (US) (4.04%).

Tandem Diabetes Care PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Tandem Diabetes Care is instrumental in guiding the company’s strategic path and ensuring accountability to its shareholders. For the 2025 annual meeting, the board size is slated to be reduced to 8 members. Ms. Robertson has held the position of Chair of the board since March 2023, and has been a board member since January 2019, bringing valuable experience from her role as a founder and General Partner at Versant Ventures.

Tandem Diabetes Care operates under a standard public company voting structure, which typically means a one-share-one-vote system. There is no public information suggesting dual-class shares or special voting rights that would grant disproportionate control to specific individuals or entities. The influence of major institutional shareholders, evident through their significant holdings, is primarily exercised through voting on proposals in proxy statements and engaging with the company’s management and board. While recent disclosures do not prominently feature specific proxy battles or activist investor campaigns, the company’s corporate governance guidelines, including stock ownership guidelines for directors and executives, are designed to align the interests of the board and management with those of the shareholders. Understanding these dynamics is key to grasping Tandem Diabetes Care ownership.

Understanding Shareholder Influence

Institutional investors often hold substantial stakes in publicly traded companies like Tandem Diabetes Care. Their voting power significantly impacts corporate decisions and strategic direction.

• Institutional investors are key Tandem Diabetes Care investors.
• Their voting power influences Tandem Diabetes Care stock ownership.
• Understanding Tandem Diabetes Care major shareholders is crucial for investors.
• The company structure facilitates shareholder engagement.

Tandem Diabetes Care Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Tandem Diabetes Care has seen significant shifts in its market standing and capital structure, influencing its ownership trends. The company's stock performance has been volatile, with a notable decline in recent months, impacting its overall valuation and investor sentiment.

Recent strategic moves and leadership changes are shaping the company's direction and potentially its ownership landscape. These developments are critical for navigating the competitive diabetes technology market.

Leadership and Financing Developments

John F. Sheridan became President and CEO in March 2019, with former CEO Kim Blickenstaff transitioning to Executive Chairman. In March 2024, the company secured $275.0 million through a private placement of Convertible Senior Notes Due 2029, a move that could impact future equity distribution upon conversion.

Product Innovations and Market Strategy

The company received FDA clearance for its Control-IQ+ technology for type 2 diabetes in February 2025 and established integration agreements with Abbott for future glucose-ketone sensors in June 2025. The 'Tandem Choice Program' for the Mobi pump concluded in February 2024 with the product's commercial launch.

Analyst Outlook and Market Position

The company's stock has experienced significant declines, leading to analyst downgrades and revised price targets. Analysts are forecasting potential gross margin improvements for 2025, which could influence the company's financial performance and investor appeal.

Understanding Tandem Diabetes Care Ownership

As a publicly traded entity, Tandem Diabetes Care's ownership is distributed among various investors, including institutional holders and individual shareholders. Understanding the Marketing Strategy of Tandem Diabetes Care can provide context for its market performance and investor relations.

Tandem Diabetes Care Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔